Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Accumulated Expenses (2018 - 2019)

Arcturus Therapeutics Holdings filings provide 2 years of Other Accumulated Expenses readings, the most recent being $560000.0 for Q3 2019.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $560000.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $560000.0, a N/A change, with the full-year FY2018 number at $674000.0, changed N/A from a year prior.
  • Other Accumulated Expenses hit $560000.0 in Q3 2019 for Arcturus Therapeutics Holdings, down from $1.3 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q2 2019 to a low of $560000.0 in Q3 2019.